Faron Pharmaceuticals Ltd has appointed Juno Jalkanen to the position of chief operating officer to help accelerate development of bexmarilimab, a potential monotherapy for patients with solid tumours. Dr Jalkanen joined Faron in 2018 as chief development officer and served as the company’s interim chief medical officer in 2021. The CMO position is now being held by Marie-Louise Fjällskog, previously CMO at Sensei Biotherapeutics Inc in the US.
Dr Jalkanen, formerly a consultant in vascular surgery at Turku Hospital, Finland, received his medical degree and PhD in molecular biology at the University of Turku. He also earned a master’s degree in economics and business administration from the Turku School of Economics.
Faron Pharmaceuticals announced the appointment on 31 January 2022.
Copyright 2022 Evernow Publishing Ltd